- Home
- ILPT vs MREO Comparison
ILPT vs MREO Comparison
Compare ILPT & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ILPT | MREO |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 378.0M | 324.6M |
| IPO Year | 2018 | N/A |
Fundamental Metrics
Financial Performance| Metric | ILPT | MREO |
|---|---|---|
| Price | $5.92 | $0.54 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $3.90 |
| AVG Volume (30 Days) | 399.5K | ★ 37.8M |
| Earning Date | 02-17-2026 | 11-10-2025 |
| Dividend Yield | ★ 3.53% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $445,459,000.00 | $500,000.00 |
| Revenue This Year | $3.00 | N/A |
| Revenue Next Year | $0.98 | $6,363.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 1.08 | N/A |
| 52 Week Low | $2.45 | $0.20 |
| 52 Week High | $6.57 | $3.26 |
Technical Indicators
Market Signals| Indicator | ILPT | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 33.38 |
| Support Level | $5.61 | $0.51 |
| Resistance Level | $6.15 | $0.78 |
| Average True Range (ATR) | 0.25 | 0.10 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 47.99 | 47.32 |
Price Performance
Historical ComparisonAbout ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).